CN105878938A - Pharmaceutical preparation for treating lung cancer and application thereof - Google Patents
Pharmaceutical preparation for treating lung cancer and application thereof Download PDFInfo
- Publication number
- CN105878938A CN105878938A CN201610370299.9A CN201610370299A CN105878938A CN 105878938 A CN105878938 A CN 105878938A CN 201610370299 A CN201610370299 A CN 201610370299A CN 105878938 A CN105878938 A CN 105878938A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- pharmaceutical preparation
- pulmonary carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of medical pharmacy, and particularly relates to a pharmaceutical preparation for treating a lung cancer and application thereof. The pharmaceutical preparation is prepared from, by weight, 15-25 parts of milkvetch roots, 10-20 parts of rhizoma chuanxiong, 20-30 parts of spica prunellae, 2-5 parts of rhizoma paridis yunnanensis, 12-20 parts of glossy privet fruit, 6-15 parts of spreading hedyotis herb, 10-20 parts of Chinese lobelia herb, 8-15 parts of radix achyranthis bidentatae, 10-20 parts of rhizoma sparganii, 20-30 parts of rhizoma curcumae, 10-25 parts of radix salvia miltiorrhiza, 2-5 parts of common dysosmatis rhizomes and roots, 10-20 parts of radix ginseng rubra, 5-15 parts of radix notoginseng, 10-20 parts of tortoise plastrons, 10-20 parts of radix bupleuri, 20-30 parts of fructus trichosanthis and 10-20 parts of licorice roots. The pharmaceutical preparation has the effects of promoting blood circulation to remove blood stasis, clearing heat and removing toxicity, reducing phlegm and resolving masses and tonifying and strengthening the spleen, it is clinically and repeatedly proved that the pharmaceutical preparation has the treatment effect on the lung cancer and has the especially obvious treatment effect on the advanced lung cancer which cannot be treated through an operation or is transferred. The pharmaceutical preparation can be used by being combined with multiple chemotherapy drugs, shrink the tumor lesions, prolong the lifetime of a tumor patient, reduce harm and side effects of a radiotherapy and a chemotherapy on a body and improve the immunity and the anti-tumor capacity of the body.
Description
Technical field
The invention belongs to field of medicaments, especially relate to a kind of pharmaceutical preparation treating pulmonary carcinoma and application thereof.
Background technology
Pulmonary carcinoma is one of global modal malignant tumor, has occupied whole pernicious swollen in industrialized country and China's many cities
The first place of the tumor cause of the death.Due to tobacco consumption and the serious environmental pollution of sustainable growth, the lung cancer morbidity rate in China's majority area
The most in rising trend with mortality rate, become one of principal disease of serious harm China residents ' health and life.Pulmonary carcinoma is main
It is divided into two classes: nonsmall-cell lung cancer (non-small cell lung cancer, NSCLC, 85%) and small cell lung cancer (small
Cell lung cancer, SCLC, 15%).NSCLC can be further divided into squamous cell carcinoma (squamous cell carcinoma,
SCC), adenocarcinoma and maxicell pulmonary carcinoma (large cell lung carcinoma, LCLC).
Pulmonary carcinoma has aggressive, and its treatment is still one of the most challenging task of medical profession.Conventional treatments include operation,
Radiation and chemotherapy.The selection of Therapeutic Method depends on that cancer types (minicell or non-small cell), advance stages and gene are special
Levy.The patient being diagnosed as pulmonary carcinoma often accepts more than one Therapeutic Method.Many genus middle and advanced stage when making a definite diagnosis, conventional Radiotherapy chemotherapy effect
Not good enough, within 5 years, survival rate is only 5%～10%.
Tcm clinical practice treatment pulmonary carcinoma is frequently with blood circulation promoting and blood stasis dispelling, the oncotherapy rule of the body resistance strengthening and constitution consolidating.It is that Chinese medicine is cured the disease that card opinion is controlled
A big characteristic, in " the new Chinese medicine guideline of clinical investigations " of inland of China, pulmonary carcinoma is divided into deficiency of vital energy phlegm-damp, the deficiency of YIN
Pyretic toxicity, deficiency of both QI and YIN, 4 kinds of syndromic types of stagnation of QI-blood.But in the Clinical controlled trial delivered, the differentiation of symptoms and signs for classification of syndrome of pulmonary carcinoma
The most unified standard, it is dialectical first with deficiency and excess as guiding principle, and deficiency syndrome mostly are the deficiency of vital energy, the deficiency of YIN；The common stagnation of QI of excess syndrome, blood stasis,
Expectorant is turbid.The form of Chinese drug for the treatment of pulmonary carcinoma mainly has oral and injection two kinds.
Summary of the invention
The present invention has blood circulation promoting and blood stasis dispelling, heat clearing away by long-term clinical practice in pulmonary carcinoma and Study of Traditional Chinese Medicine prescription, this prescription
Removing toxic substances, dissipating phlegm and resolving masses, effect of tonification spleen invigorating, repeatedly confirm the prescription therapeutic effect to pulmonary carcinoma of the present invention, the most right
The therapeutic effect that can not perform the operation or occur the pulmonary carcinoma of transfer late period is especially apparent.
Specifically, the technical scheme is that and be achieved in that:
A kind of pharmaceutical preparation treating pulmonary carcinoma, includes than its composition according to weight fraction:
Radix Astragali 15-25 part, Rhizoma Chuanxiong 10-20 part, Spica Prunellae 20-30 part, Rhizoma Paridis 2-5 part, Fructus Ligustri Lucidi 12-20 part,
Herba Hedyotidis Diffusae 6-15 part, Herba Lobeliae Chinensis 10-20 part, Radix Achyranthis Bidentatae 8-15 part, Rhizoma Sparganii 10-20 part, Rhizoma Curcumae 20-30 part is red
Ginseng 10-25 part, Radix et Rhizoma Dysosmatis 2-5 part, Radix Ginseng Rubra 10-20 part, Typhonium flagelliforme (Lodd.) Blume 5-15 part, Carapax et Plastrum Testudinis 10-20 part, Radix Bupleuri 10-20
Part, Fructus Trichosanthis 20-30 part, Radix Glycyrrhizae 10-20 part.
In order to obtain preferable technique effect further, a kind of pharmaceutical preparation treating pulmonary carcinoma, according to weight fraction than its composition
Including:
The Radix Astragali 20 parts, Rhizoma Chuanxiong 15 parts, Spica Prunellae 25 parts, Rhizoma Paridis 3 parts, Fructus Ligustri Lucidi 15 parts, Herba Hedyotidis Diffusae 12
Part, Herba Lobeliae Chinensis 15 parts, Radix Achyranthis Bidentatae 12 parts, Rhizoma Sparganii 15 parts, Rhizoma Curcumae 25 parts, Radix Salviae Miltiorrhizae 20 parts, Radix et Rhizoma Dysosmatis 3 parts, Radix Ginseng Rubra 15
Part, Typhonium flagelliforme (Lodd.) Blume 10 parts, Carapax et Plastrum Testudinis 15 parts, Radix Bupleuri 15 parts, Fructus Trichosanthis 25 parts, 15 parts of Radix Glycyrrhizae.
In order to obtain preferable technique effect further, a kind of pharmaceutical preparation treating pulmonary carcinoma, according to weight fraction than its composition
Including:
The Radix Astragali 16 parts, Rhizoma Chuanxiong 19 parts, Spica Prunellae 28 parts, Rhizoma Paridis 2 parts, Fructus Ligustri Lucidi 18 parts, Herba Hedyotidis Diffusae 13
Part, Herba Lobeliae Chinensis 12 parts, Radix Achyranthis Bidentatae 14 parts, Rhizoma Sparganii 12 parts, Rhizoma Curcumae 28 parts, Radix Salviae Miltiorrhizae 19 parts, Radix et Rhizoma Dysosmatis 5 parts, Radix Ginseng Rubra 18
Part, Typhonium flagelliforme (Lodd.) Blume 12 parts, Carapax et Plastrum Testudinis 18 parts, Radix Bupleuri 18 parts, Fructus Trichosanthis 28 parts, 12 parts of Radix Glycyrrhizae.
In order to obtain preferable technique effect further, a kind of pharmaceutical preparation treating pulmonary carcinoma, according to weight fraction than its composition
Including:
The Radix Astragali 18 parts, Rhizoma Chuanxiong 12 parts, Spica Prunellae 22 parts, Rhizoma Paridis 4 parts, Fructus Ligustri Lucidi 16 parts, Herba Hedyotidis Diffusae 12
Part, Herba Lobeliae Chinensis 16 parts, Radix Achyranthis Bidentatae 12 parts, Rhizoma Sparganii 12 parts, Rhizoma Curcumae 22 parts, Radix Salviae Miltiorrhizae 22 parts, Radix et Rhizoma Dysosmatis 4 parts, Radix Ginseng Rubra 12
Part, Typhonium flagelliforme (Lodd.) Blume 6 parts, Carapax et Plastrum Testudinis 20 parts, Radix Bupleuri 19 parts, Fructus Trichosanthis 22 parts, 18 parts of Radix Glycyrrhizae.
In order to obtain preferable technique effect further, a kind of pharmaceutical preparation treating pulmonary carcinoma, according to weight fraction than its composition
Including:
The Radix Astragali 15 parts, Rhizoma Chuanxiong 10 parts, Spica Prunellae 30 parts, Rhizoma Paridis 5 parts, Fructus Ligustri Lucidi 12 parts, Herba Hedyotidis Diffusae 15
Part, Herba Lobeliae Chinensis 20 parts, Radix Achyranthis Bidentatae 9 parts, Rhizoma Sparganii 20 parts, Rhizoma Curcumae 20 parts, Radix Salviae Miltiorrhizae 125 parts, Radix et Rhizoma Dysosmatis 2 parts, Radix Ginseng Rubra 10
Part, Typhonium flagelliforme (Lodd.) Blume 15 parts, Carapax et Plastrum Testudinis 10 parts, Radix Bupleuri 20 parts, Fructus Trichosanthis 20 parts, 12 parts of Radix Glycyrrhizae.
Above material medicine is extracted is prepared as pharmaceutically acceptable preparation.
Affiliated preparation includes decoction, granule, capsule, tablet, powder, injection.
The application in preparing lung-cancer medicament of the above preparation.Preferably, described preparation is at preparation treatment non-small cell lung cancer drug
In application.
The preparation method of above pharmaceutical preparation is: weighed up according to weight by traditional Chinese medicinal material raw materials, with soak by water 1-3 time, every time
30-60 minute, filtering, merging filtrate, filtrate reduced in volume is equivalent to raw medicinal herbs amount 1 weight portion to every 1 milliliter, to obtain final product
Decoction；Or sterilized, filling bottle, obtain oral liquid；Or concentrate, be dried to dry cream, add starch, pulverize, mixing,
Crossing 80 mesh sieves, with 95% ethanol wet granulation, less than 80 DEG C are dried, and granulate makes granule；Or conventional method adds
Enter magnesium stearate, mixing, tabletting, coating, obtain tablet；Or addition conventional excipients, loads capsule, obtains capsule
Agent.
Traditional Chinese medicinal material raw materials is weighed up according to weight, after soak with ethanol 8-12 hour, by 20-25 times of weight 75-85% second
1-3 backflow of alcohol, refluxes 1-1.5 hour after each micro-boiling, filters, and recovery ethanol, to without alcohol taste, obtains extract；By often
Rule method makes decoction, oral liquid, granule, tablet, pill, powder, injection or capsule.
The pharmacological action of the raw materials used medicine of the present invention:
The Radix Astragali, sweet, tepor；Return spleen, lung meridian.Effect: benefit defends consolidating superficial resistance, tonifying Qi and lifting yang, promoting pus discharge and tissue regeneration strengthening, inducing diuresis to remove edema.
Curing mainly:, anorexia and loose stool weak for the deficiency of vital energy, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, from juice night sweat, blood deficiency and yellow complexion, carbuncle of yin nature is unrestrained swollen,
Deficiency of vital energy edema, interior-heat is quenched one's thirst.There is enhancing immunity, antitumor action, and the key medicine of the gas for spleen reinforcing lung, modern pharmacy
Research, the Radix Astragali is mainly by enhancing dendritic cell vaccination effect, the effect of regulation Th1/Th2 cytokine dynamic equilibrium
Treatment pulmonary carcinoma.
Rhizoma Chuanxiong, pungent, temperature.Return liver, gallbladder, pericardium channel.Effect: blood-activating and qi-promoting, wind-expelling pain-stopping.Cure mainly: for menstruation not
Tune, hypochondriac pain, the thoracic obstruction, skin infection swell and ache, traumatic injury, headache, rheumatic arthralgia.Can blood circulation promoting and blood stasis dispelling with regulating menstruation, can manage it again
Gas dissipating depression of QI and pain relieving, for the gas medicine in blood.
Spica Prunellae, pungent, bitter, cold.Return liver, gallbladder meridian.Effect: clearing away liver-fire, Disperse hepatic depression, suppressing the hyperactive liver sun.Cure mainly: for mesh
Red swell and ache, mesh pearl nyctalgia, scrofula goiter, dizziness and headache.
Rhizoma Paridis, bitter, it is slightly cold.Slightly poisonous.Enter Liver Channel.Function cures mainly: heat-clearing and toxic substances removing, detumescence, spasmolytic.
Fructus Ligustri Lucidi, sweet；Bitter；Cool in nature.Gui Jing: Liver Channel；Kidney channel.Effect: liver and kidney tonifying；Clearind deficient heat；Improving eyesight.Cure mainly:
Light-headedness；Soreness of the waist and knees；Seminal emission；Tinnitus；Early whitening of beard and hair, osteopyrexia and fever；Poor vision.
Herba Hedyotidis Diffusae, micro-hardship, sweet；Return stomach, large intestine, Liver Channel.Relieve internal heat anticancer, antiinflammatory detumescent, clearing away heat-damp and promoting diuresis.
Herba Scutellariae Barbatae, pungent, bitter, cold.Return lung, liver, kidney channel.Heat-clearing and toxic substances removing, blood stasis dispelling diuresis.For furuncle swelling toxin, throat
Swell and ache, venom, fall and flutter the pain of injury, edema, jaundice.
Radix Achyranthis Bidentatae, bitter, sour, flat.Return liver, kidney channel.Effect: blood circulation promoting and blood stasis dispelling, invigorating the liver and kidney, bone and muscle strengthening, relieving stranguria by diuresis, draws
Blood is descending.Cure mainly: for menoxenia, dysmenorrhea, amenorrhea, postpartum stagnation, traumatic pain, soreness of waist and knee joint, lower limb are weak,
Dysuria, drenches and drips puckery pain, spits blood, epistaxis, toothache, aphtha, dizziness of having a headache.
Rhizoma Sparganii, bitter, flat.Return liver, spleen channel.Effect: removing blood stasis, promoting the circulation of QI to relieve pain.Cure mainly: suffer from abdominal pain for amenorrhea,
Abdominal mass is gathered, abdominal pain due to retention of food.
Rhizoma Curcumae, pungent, bitter, temperature.Return liver, spleen channel.Effect: removing blood stasis, promoting the circulation of QI to relieve pain.Cure mainly: suffer from abdominal pain for amenorrhea,
Abdominal mass is gathered, abdominal pain due to retention of food.
Radix Salviae Miltiorrhizae, bitter, it is slightly cold.GUIXIN, pericardium, Liver Channel.Effect: blood circulation promoting and blood stasis dispelling, removing heat from blood eliminating carbuncle, nourishing blood to tranquillize the mind.Cure mainly:
For menoxenia, trusted subordinate's pain, abdominal mass accumulation, beriberoid pyretic arthralgia, skin infection swells and ache, and agitation is insomnia, cardiopalmus, insomnia.
Radix et Rhizoma Dysosmatis bitter in the mouth, pungent, cool in nature.Poisonous.Return lung, Liver Channel.Effect: dissipating phlegm and resolving masses, heat-clearing and toxic substances removing, removing blood stasis to reduce swelling.
Cure mainly: cure mainly cough due to fluid-retention, laryngopharynx swelling and pain, mumps, scrofula goiter, carbuncle furuncle, venom, traumatic injury, wind
Poison paralysis, breast carcinoma.
Radix Ginseng Rubra, hardship sweet, micro-, temperature.Return spleen, lung, heart channel.Effect: QI invigorating, YIN nourishing, benefit blood, promote the production of body fluid, heart tonifying, strong
Stomach, calmness.Cure mainly: for weak body and prostration, cold extremities faint pulse, QI failing to control blood, metrostaxis；Heart failure, cardiogenic shock.
Typhonium flagelliforme (Lodd.) Blume, hardship sweet, micro-, temperature.GUIXIN, liver, spleen channel.Removing stasis to stop bleeding, reducing swelling and alleviating pain.Containing arasaponin, β-olive
The fragrant anti-cancer active matter such as alkene, trace element-selenium；The Rb1 of arasaponin 120ug/ml concentration can make the tumor cell of cultivation
92% is suppressed, and the suppression ratio of Panax Notoginseng saponin R d is then 79%；The hepatoma carcinoma cell cultivated is had and significantly presses down by Panax Notoginseng saponin R h1
Make and use；Panax Notoginseng saponin R h2 has stronger anti-tumor activity, and Denucleation can be induced to become non-cancerous cells.Radix Notoginseng soap
Glycosides and Radix Notoginseng polysaccharide energy enhancing human body immunity function, have certain assosting effect to treatment cancer
Carapax et Plastrum Testudinis is salty, sweet, flat, enters liver, kidney two warp.Primary efficacy is nourishing YIN for suppressing the hyperactive YANG, replenishing YIN and removing heat, replenishing kidney and strengthening bone.
Radix Bupleuri, nature and flavor: bitter flat, Gui Jing, enter liver, gallbladder meridian.Function: deliver, bring down a fever, soothing the liver, resolving depression, yang invigorating.With
White rabbit anticarcinogenic effect purebred to New Zealand studied by Radix Bupleuri, finds its suppression tumor necrosis factor (TNF) growth, extends animal
Life span.
Fructus Trichosanthis, sweet, cold.Return lung, stomach, large intestine channel.Effect: removing heat from the lung and dissipating phlegm, promoting the circulation of QI the chest stuffiness relieving；Moistening the lung and resolving phlegm, laxation leads to
Just, mass dissipating and swelling eliminating.Cure mainly: for phlegm-heat cough, the thoracic obstruction, blocked-up chest, chest and diaphragm painful abdominal mass pain, dryness of the intestine constipation, lung abscess, acute mastitis.
Radix Glycyrrhizae, sweet, flat.GUIXIN, spleen, lung, stomach warp.Effect: invigorating the spleen and replenishing QI, nourishing the lung to arrest cough, heat-clearing and toxic substances removing, alleviate
Pain relieving, relaxes the property of medicine.Cure mainly: for weakness of the spleen and stomach, shortness of breath and fatigue, severe palpitation, cough expectorant is few, pathopyretic ulcer, medicine
Food poisoning, gastral cavity abdomen shoot, limb pain twin.
This prescription has blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, dissipating phlegm and resolving masses, effect of tonification spleen invigorating, repeatedly confirms the present invention's
The prescription therapeutic effect to pulmonary carcinoma, especially can not perform the operation to late period or occur the therapeutic effect of the pulmonary carcinoma of transfer to be especially apparent.Can
It is applied in combination with Treated with Chemotherapeutic Drugs thing, reduces tumor focus, extend tumor patient life cycle；Reduce the chemicotherapy wound to health
Evil and side effect, improve immunity and the anti-tumor capacity of health simultaneously.
Detailed description of the invention
Embodiment 1
A kind of pharmaceutical preparation treating pulmonary carcinoma, includes than its composition according to weight fraction:
The Radix Astragali 20 parts, Rhizoma Chuanxiong 15 parts, Spica Prunellae 25 parts, Rhizoma Paridis 3 parts, Fructus Ligustri Lucidi 15 parts, Herba Hedyotidis Diffusae 12
Part, Herba Lobeliae Chinensis 15 parts, Radix Achyranthis Bidentatae 12 parts, Rhizoma Sparganii 15 parts, Rhizoma Curcumae 25 parts, Radix Salviae Miltiorrhizae 20 parts, Radix et Rhizoma Dysosmatis 3 parts, Radix Ginseng Rubra 15
Part, Typhonium flagelliforme (Lodd.) Blume 10 parts, Carapax et Plastrum Testudinis 15 parts, Radix Bupleuri 15 parts, Fructus Trichosanthis 25 parts, 15 parts of Radix Glycyrrhizae.
Above Chinese medicine composition is prepared as decoction, its concrete preparation method:
Being weighed up according to part by weight by above traditional Chinese medicinal material raw materials, add pure water and soak, the water surface is higher than powder 3-5cm, soaks 2
After individual hour, decocting 2 times, 1.5 hours for the first time, 1 hour for the second time, merge decoction liquor, medicinal liquid divides two parts, the most each
Take portion.
Embodiment 2
A kind of pharmaceutical preparation treating pulmonary carcinoma, includes than its composition according to weight fraction:
The Radix Astragali 16 parts, Rhizoma Chuanxiong 19 parts, Spica Prunellae 28 parts, Rhizoma Paridis 2 parts, Fructus Ligustri Lucidi 18 parts, Herba Hedyotidis Diffusae 13
Part, Herba Lobeliae Chinensis 12 parts, Radix Achyranthis Bidentatae 14 parts, Rhizoma Sparganii 12 parts, Rhizoma Curcumae 28 parts, Radix Salviae Miltiorrhizae 19 parts, Radix et Rhizoma Dysosmatis 5 parts, Radix Ginseng Rubra 18
Part, Typhonium flagelliforme (Lodd.) Blume 12 parts, Carapax et Plastrum Testudinis 18 parts, Radix Bupleuri 18 parts, Fructus Trichosanthis 28 parts, 12 parts of Radix Glycyrrhizae
Above Chinese medicine composition is prepared as granule, its concrete preparation method:
Being weighed up according to weight by traditional Chinese medicinal material raw materials, add pure water and soak, the water surface is higher than powder 3-5cm, after soaking 2 hours,
Decocting 2 times, 1 hour for the first time, 0.5 hour for the second time, merge decoction liquor, being evaporated to relative density is 1.05, standby
With；Add the ethanol of 1.5 times 75% after decocting liquid cooling, fully mix, stand overnight so that it is precipitation, take on it after 24h
Clear liquid, retains precipitate；Precipitate is cleaned with a small amount of 60% ethanol, and washing liquid merges with filtrate, after decompression recycling ethanol, subtracts
It is 1.20 that pressure is concentrated into relative density, stands 24h, precipitation, filters；Filtrate mix homogeneously, low-temperature evaporation is to paste, dry
Dry extractum powder adds lactose and dextrin, then wet granulation, obtains granule.
Embodiment 3
A kind of pharmaceutical preparation treating pulmonary carcinoma, includes than its composition according to weight fraction:
The Radix Astragali 18 parts, Rhizoma Chuanxiong 12 parts, Spica Prunellae 22 parts, Rhizoma Paridis 4 parts, Fructus Ligustri Lucidi 16 parts, Herba Hedyotidis Diffusae 12
Part, Herba Lobeliae Chinensis 16 parts, Radix Achyranthis Bidentatae 12 parts, Rhizoma Sparganii 12 parts, Rhizoma Curcumae 22 parts, Radix Salviae Miltiorrhizae 22 parts, Radix et Rhizoma Dysosmatis 4 parts, Radix Ginseng Rubra 12
Part, Typhonium flagelliforme (Lodd.) Blume 6 parts, Carapax et Plastrum Testudinis 20 parts, Radix Bupleuri 19 parts, Fructus Trichosanthis 22 parts, 18 parts of Radix Glycyrrhizae.
Above Chinese medicine composition is prepared as tablet, its concrete preparation method:
Traditional Chinese medicinal material raw materials is weighed up according to weight, after soak with ethanol 8-12 hour, by 20-25 times of weight 75-85%
2 backflows of ethanol, reflux 1-1.5 hour after each micro-boiling, filter, and recovery ethanol, to without alcohol taste, obtains extract；Low
Temperature is evaporated to paste, wet granulation, is dried, adds appropriate median chain triglyceride oil and tween 80, mannitol, to obtain final product
Tablet.
Embodiment 4
A kind of pharmaceutical preparation treating pulmonary carcinoma, includes than its composition according to weight fraction:
The Radix Astragali 15 parts, Rhizoma Chuanxiong 10 parts, Spica Prunellae 30 parts, Rhizoma Paridis 5 parts, Fructus Ligustri Lucidi 12 parts, Herba Hedyotidis Diffusae 15
Part, Herba Lobeliae Chinensis 20 parts, Radix Achyranthis Bidentatae 9 parts, Rhizoma Sparganii 20 parts, Rhizoma Curcumae 20 parts, Radix Salviae Miltiorrhizae 125 parts, Radix et Rhizoma Dysosmatis 2 parts, Radix Ginseng Rubra 10
Part, Typhonium flagelliforme (Lodd.) Blume 15 parts, Carapax et Plastrum Testudinis 10 parts, Radix Bupleuri 20 parts, Fructus Trichosanthis 20 parts, 12 parts of Radix Glycyrrhizae.
Above Chinese medicine composition is prepared as capsule, its concrete preparation method:
Traditional Chinese medicinal material raw materials is weighed up according to weight, after soak with ethanol 10 hours, returns for 2 times with 22 times of weight 75-85% ethanol
Stream, refluxes 1-1.5 hour after each micro-boiling, filters, and recovery ethanol, to without alcohol taste, obtains extract；Low-temperature evaporation is to thick
Paste, wet granulation, it is dried, adds appropriate powder-beta-dextrin and binding agent, mannitol, obtain capsule.
Embodiment 5 animal pharmacodynamics test
5.1, the foundation of mouse model
5.1.1 recovery Lewis lung cancer cell strain C57BL/6 mice interior generation
Take out frozen Lewis lung cancer cell strain, be shaken gently in cryopreservation tube is placed in 37 DEG C of electric heating constant-temperature water-bath tanks.
After it melts, quick sucking-off cell suspension, injects containing 10% hyclone, l00 μ/ml streptomycin, l00 μ/ml penicillium sp
The centrifuge tube of the DMEM in high glucose culture medium of element, conventional centrifugal.Choose 3 C57BL/6 mices, right front oxter skin of sterilizing
Skin, takes 0.2ml (counting about 1 × 106-2×106Individual oncocyte) oncocyte suspension is inoculated in subcutaneous.Take and inoculate Lewis
The pulmonary carcinoma lotus tumor C57BL/6 mice of 10 days, under aseptic condition, de-cervical vertebra is put to death.Tumor tissue is shredded, by the ratio of 1:3
Tumor tissues and normal saline are made homogenate by example, are sieved through with 200 mesh cells and filter, obtain oncocyte suspension, 1500rpm from
Heart 5min, makes oncocyte density and is about l × l07The cell suspension of/ml, is inoculated in armpit skin before the mice right side.Same sample prescription
Method passes on 3 times.
5.1.2 set up Lewis lung cancer mouse model
Taking and inoculate the Lewis lung cancer lotus tumor C57BL/6 mice of 10 days, under aseptic condition, de-cervical vertebra is put to death.By tumor tissue
Shred, in the ratio of 1:3, tumor tissues and normal saline are made homogenate, be sieved through filter with 200 mesh cells, obtain tumor thin
Born of the same parents' suspension, 1500rpm is centrifuged 5min, makes oncocyte concentration and is about l × l07The cell suspension of/ml.By prepare
Tumor cell suspension is inoculated in before the mice right side of experiment under axil skin, every inoculation 0.2ml.Said process is after tumor resection
Complete in 1h.
5.2, it is grouped and is administered
When within the 2nd day, carrying out pharmaceutical intervention after inoculation, it is randomly divided into 5 groups, often group 10, is administered as follows:
Normal saline group: use every day same time period gavage mode, normal saline 0.4ml/, 1 times/day.
Chinese medicine low dose group, the dosage of gavage 20mg/kg/ day；
Dosage group in Chinese medicine, the dosage of gavage 50mg/kg/ day；
Chinese medicine high dose group, the dosage of gavage 80mg/kg/ day；
Positive drug group, cisplatin+vinorelbine, the dosage of 0.5ml/kg/ day.
5.3, index observing
Each group mice is fed 21 days, and de-cervical approach puts to death all mices.Weigh Mouse Weight, completely strip transplanted tumor body, lungs,
Spleen, thymus, remove the adhesion organizations such as surface blood stains, fat, fascia, weigh its weight with electronic balance respectively.Lungs
Invading and steep in Bouis liquid, count after 24h the number of metastatic tumor under microscopic visualization between pulmonary front, reverse side and the lobe of the lung.
Take Lung metastases tissue, use paraffin embedding, section, HE dyeing, rear light Microscopic observation.Transplanted tumor divides two parts, first
Divide and take the 1/3 of tuberosity volume, put in the cryovial that sterilization and DEPC processed in advance, be stored in liquid nitrogen, be used as the most glimmering
Fluorescent Quantitative PCR is tested；Part II takes the residue 2/3 of tuberosity and is put in (p in 10% neutral buffered formalin solution
H7.4).Spleen and thymus are soaked in 10% neutral buffered (p H7.4) formalin solution.
The most each group of tumour inhibiting rate to Lewis lung cancer mice
Tumour inhibiting rate computing formula:
Tumour inhibiting rate=(normal saline group average tumor weight-each treatment group average tumor weight)/normal saline group average tumor weight × 100%；
5.3.2 observe and immune organ (spleen and thymus) is affected
Thymus index=thymic weight/body weight；
Spleen index=spleen weight/body weight.
5.4, experimental result
Each group Lewis lung cancer mice day by day occur the sparse tarnish of fur, movable lazy, be slow in action, assemble in groups, mesh
The phenomenons such as light is dull, feed minimizing, wherein, the above Symptoms of Chinese drug-treated group is the lightest, is secondly normal saline group, positive drug
The symptom of thing group is the most serious；Each group body weight all has increase in various degree, and the body weight increase that wherein Chinese medicine is respectively organized is the most obvious,
Illustrating that Chinese medicine preparation can improve mice general status, increase mice with tumor body weight, it is secondary that positive drug group shows obvious chemotherapy poison
Effect.
The most each group to lewis lung cancer in mice tumor-inhibiting action
The change of Lewis mouse tumor weight: each experimental group all can alleviate mouse tumor weight, compared with normal saline group, each dosage Chinese medicine
Group, positive drug group is respectively provided with significant difference (P ＜ 0.01), is specifically shown in Table 1.Experiment shows: Chinese medicine of the present invention and the positive
Medicine all can suppress the transfer of pulmonary carcinoma.
Each group of table 1. is to lewis lung cancer in mice tumor-inhibiting action result
Note: compare with normal saline group, * * P ＜ 0.01, * P ＜ 0.05.
5.4.2 the impact on immune organ
Root is compared with normal saline group, and each dosage Chinese drug-treated group can increase mouse thymus index, spleen index, and statistically significant (P
＞ 0.05)；Positive drug group reduces thymus index, spleen index, not statistically significant (P ＞ 0.05).Result shows: this
Invention Chinese medicine has and necessarily increases thymus index, spleen index effect.(being shown in Table 2).
Each group of impact on lewis lung cancer in mice immune organ weight of table 2.
| Packet | Index and spleen index (mg/g) | Thymus index (mg/g) |
| Normal saline group | 9.01±3.26 | 1.05±0.32 |
| Chinese medicine low dose group | 11.54±3.10* | 1.17±0.35** |
| Dosage group in Chinese medicine | 12.32±2.28** | 1.29±0.37* |
| Chinese medicine high dose group | 13.09±2.58* | 1.35±0.28* |
| Positive drug group | 6.83±50.29 | 0.90±0.21 |
Note: compare with normal saline group, * P ＜ 0.05.
Embodiment 6: clinical experiment part
6.1, physical data
Choose in January, 2014 in December, 2015 the court patients with lung cancer 50 example, male 29 example, women 21 example, age
35-70 year, 56.7 years old mean age.Clinical stages is example .III phase 13 II phase 12 example, IV phase 25 example.
Diagnostic criteria: meet the one of the following, may establish that clinical diagnosis: (1) x-ray rabat is shown in that there is isolatism in pulmonary
Tuberosity or lump shade, its edge is gyrus shape, leaflet and burr shape, and in a short time (after generally 2 courses for the treatment of) by
Cumulative big person, can get rid of tuberculosis or other inflammatory lesion person the most after the positive Drug therapy of short-term；(2) section pneumonia exists
Develop into segmental atelectasis (after generally 2 courses for the treatment of) in a short time, or segmental atelectasis develop into full pulmonary atelectasis person in a short time,
Or in the pulmonary of its corresponding site, lump occurs, particularly growth lump person；(3) above-mentioned pulmonary lesions with metastasis,
Neighbouring device pipe is invaded or pressure symptom shower, as adjacent bone destruction, hilus pulumonis or mediastinal lymph nodes significantly increase, sends out in a short time
The caval vein stress disorders of exhibition, homonymy recurrent laryngeal nerve fiber crops thin (after getting rid of tuberculosis and aortic disease) and napex sympathetic ganglion
(eliminating operation wound), brachial plexus nerve, every nerve infiltration disease etc..
6.2, it is grouped and treats
50 example patients are randomly divided into 2 groups, and respectively treatment by Chinese herbs group and matched group, without significant difference between two groups, having can
Ratio property, Therapeutic Method is as follows:
Treatment by Chinese herbs group: the pharmaceutical preparation in embodiment of the present invention 1-4,2 times on the one, 1 month be a course for the treatment of.
Matched group: select one from platinum class preparation and vinorelbine, gemzar, docetaxel, paclitaxel, pemetrexed, one
Zhou Yici, 1 month is a course for the treatment of.
6.3, therapeutic effect
Index of assessment of curative effect: 1. tcm syndrome；2. quality of life: U.S.'s lung cancer therapy functional evaluation scale 4.0 Chinese edition,
Ka Shi scoring, body weight change；3. treatment terminates rear acute and subacute toxicity observation table.
Efficacy assessment standard
Complete incidence graph (completely response, CR): cases of complete remission；
Part alleviates (partial response, PR): tumor regression more than 50%,；
Stable (stable disease, SD): pathological changes is without increasing, without being clearly better；
Progress (progressive disease, PD): focus expands or new focus occurs
Total number of cases × 100% of effective percentage=CR+PR/.
The treatment by Chinese herbs group therapeutic effect to pulmonary carcinoma, passes judgment on from effective percentage, and treatment by Chinese herbs group (72%) is slightly better than matched group (64%),
For the quality of life of patient, the patient for the treatment of by Chinese herbs group is significantly larger than the quality of life of matched group.
Table 3. clinical treatment situation
| Packet (case load) | CR | PR | SD | PD | Effective percentage |
| Treatment by Chinese herbs group (25) | 3 | 15 | 5 | 2 | 72.0% |
| Matched group (25) | 2 | 14 | 3 | 6 | 64.0% |
6.4, model case
Case 1: Wang, man, 55 years old, in April, 2014 went to a doctor, routine examination: superficial lymph is tied without enlargement, cardiopulmonary
Abdominal part is not and positive sign.Auxiliary examination: breast CT is shown in the multiple lump of right lung, tuberosity shadow, differs in size, density unevenness,
Edge is the most whole, sees and organize lymphadenectasis more in mediastinum；Head nuclear magnetic resonance (MRI), Whole Body Bone Imaging, abdominal CT are equal
Discovery without exception.Lung bioplsy under VATS, pathology prompts for lung gland.Agree to treat into group, use medicine system of the present invention
Agent, takes 30 days courses for the treatment of.Patients Patients's sensory effect is pretty good.After adhering to continuing medication 2 months, check, according to reality
Body tumor the standard of curative effect evaluation (RECIST) Estimating curative effect, therapeutic evaluation is to have slight nausea and vomiting in PR, and therapeutic process,
Without obvious alopecia, patients ' life quality is higher.
Case 2: grandson, man, 43 years old, in June, 2015 went to a doctor, and main suit coughs yellow viscous expectorant, gasps for breath, sleeps poor,
Appetite is poor, and dry stool is dry, and lassitude is unable, dim complexion.Routine examination: superficial lymph is tied without enlargement, cardiopulmonary abdominal part
Not and positive sign.Auxiliary examination: breast CT shows that central type carcinoma of lung recurs, it is impossible to operative treatment, it is impossible to tolerance chemotherapy；Warp
Agree to treat into group, use pharmaceutical preparation of the present invention, take 30 days courses for the treatment of.Patients Patients's sensory effect is pretty good.Adhere to
After continuing medication 3 months, stable disease, the most continuous use 10 months, quality of life is good, and above-mentioned every disease all disappears
Losing, according to solid tumor the standard of curative effect evaluation (RECIST) Estimating curative effect, therapeutic evaluation is PR,
Above the specific embodiment of the present invention is described in detail, but described content has been only presently preferred embodiments of the present invention,
It is not to be regarded as the practical range for limiting the present invention.All impartial changes made according to the present patent application scope and improvement etc.,
Within all should still belonging to the patent covering scope of the present invention.
Claims (9)
1. the pharmaceutical preparation treating pulmonary carcinoma, it is characterised in that: include than its composition according to weight fraction: Radix Astragali 15-25 part,
Rhizoma Chuanxiong 10-20 part, Spica Prunellae 20-30 part, Rhizoma Paridis 2-5 part, Fructus Ligustri Lucidi 12-20 part, Herba Hedyotidis Diffusae 6-15 part,
Herba Lobeliae Chinensis 10-20 part, Radix Achyranthis Bidentatae 8-15 part, Rhizoma Sparganii 10-20 part, Rhizoma Curcumae 20-30 part, Radix Salviae Miltiorrhizae 10-25 part, Radix et Rhizoma Dysosmatis 2-5
Part, Radix Ginseng Rubra 10-20 part, Typhonium flagelliforme (Lodd.) Blume 5-15 part, Carapax et Plastrum Testudinis 10-20 part, Radix Bupleuri 10-20 part, Fructus Trichosanthis 20-30 part, Radix Glycyrrhizae
10-20 part.
A kind of pharmaceutical preparation treating pulmonary carcinoma the most according to claim 1, it is characterised in that: according to weight fraction than its composition
Including: the Radix Astragali 20 parts, Rhizoma Chuanxiong 15 parts, Spica Prunellae 25 parts, Rhizoma Paridis 3 parts, Fructus Ligustri Lucidi 15 parts, Herba Hedyotidis Diffusae 12
Part, Herba Lobeliae Chinensis 15 parts, Radix Achyranthis Bidentatae 12 parts, Rhizoma Sparganii 15 parts, Rhizoma Curcumae 25 parts, Radix Salviae Miltiorrhizae 20 parts, Radix et Rhizoma Dysosmatis 3 parts, Radix Ginseng Rubra 15
Part, Typhonium flagelliforme (Lodd.) Blume 10 parts, Carapax et Plastrum Testudinis 15 parts, Radix Bupleuri 15 parts, Fructus Trichosanthis 25 parts, 15 parts of Radix Glycyrrhizae.
A kind of pharmaceutical preparation treating pulmonary carcinoma the most according to claim 1, it is characterised in that: according to weight fraction than its composition
Including: the Radix Astragali 16 parts, Rhizoma Chuanxiong 19 parts, Spica Prunellae 28 parts, Rhizoma Paridis 2 parts, Fructus Ligustri Lucidi 18 parts, Herba Hedyotidis Diffusae 13
Part, Herba Lobeliae Chinensis 12 parts, Radix Achyranthis Bidentatae 14 parts, Rhizoma Sparganii 12 parts, Rhizoma Curcumae 28 parts, Radix Salviae Miltiorrhizae 19 parts, Radix et Rhizoma Dysosmatis 5 parts, Radix Ginseng Rubra 18
Part, Typhonium flagelliforme (Lodd.) Blume 12 parts, Carapax et Plastrum Testudinis 18 parts, Radix Bupleuri 18 parts, Fructus Trichosanthis 28 parts, 12 parts of Radix Glycyrrhizae.
A kind of pharmaceutical preparation treating pulmonary carcinoma the most according to claim 1, it is characterised in that: according to weight fraction than its composition
Including: the Radix Astragali 18 parts, Rhizoma Chuanxiong 12 parts, Spica Prunellae 22 parts, Rhizoma Paridis 4 parts, Fructus Ligustri Lucidi 16 parts, Herba Hedyotidis Diffusae 12
Part, Herba Lobeliae Chinensis 16 parts, Radix Achyranthis Bidentatae 12 parts, Rhizoma Sparganii 12 parts, Rhizoma Curcumae 22 parts, Radix Salviae Miltiorrhizae 22 parts, Radix et Rhizoma Dysosmatis 4 parts, Radix Ginseng Rubra 12
Part, Typhonium flagelliforme (Lodd.) Blume 6 parts, Carapax et Plastrum Testudinis 20 parts, Radix Bupleuri 19 parts, Fructus Trichosanthis 22 parts, 18 parts of Radix Glycyrrhizae.
A kind of pharmaceutical preparation treating pulmonary carcinoma the most according to claim 1, it is characterised in that: according to weight fraction than its composition
Including: the Radix Astragali 15 parts, Rhizoma Chuanxiong 10 parts, Spica Prunellae 30 parts, Rhizoma Paridis 5 parts, Fructus Ligustri Lucidi 12 parts, Herba Hedyotidis Diffusae 15
Part, Herba Lobeliae Chinensis 20 parts, Radix Achyranthis Bidentatae 9 parts, Rhizoma Sparganii 20 parts, Rhizoma Curcumae 20 parts, Radix Salviae Miltiorrhizae 125 parts, Radix et Rhizoma Dysosmatis 2 parts, Radix Ginseng Rubra 10
Part, Typhonium flagelliforme (Lodd.) Blume 15 parts, Carapax et Plastrum Testudinis 10 parts, Radix Bupleuri 20 parts, Fructus Trichosanthis 20 parts, 12 parts of Radix Glycyrrhizae.
6. according to a kind of pharmaceutical preparation treating pulmonary carcinoma described in claim 1-5, it is characterised in that: described material medicine is through carrying
Take and be prepared as pharmaceutically acceptable preparation.
A kind of pharmaceutical preparation treating pulmonary carcinoma the most according to claim 6, it is characterised in that: affiliated preparation include decoction,
Granule, capsule, tablet, powder, injection.
A kind of pharmaceutical preparation treating pulmonary carcinoma the most according to claim 6, it is characterised in that: described preparation is at preparation treatment lung
Application in cancer drug.
A kind of pharmaceutical preparation treating pulmonary carcinoma the most according to claim 8, it is characterised in that: described preparation is non-in preparation treatment
Application in small cell lung cancer medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610370299.9A CN105878938A (en) | 2016-05-30 | 2016-05-30 | Pharmaceutical preparation for treating lung cancer and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610370299.9A CN105878938A (en) | 2016-05-30 | 2016-05-30 | Pharmaceutical preparation for treating lung cancer and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105878938A true CN105878938A (en) | 2016-08-24 |
Family
ID=56708967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610370299.9A Withdrawn CN105878938A (en) | 2016-05-30 | 2016-05-30 | Pharmaceutical preparation for treating lung cancer and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105878938A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107684566A (en) * | 2017-04-08 | 2018-02-13 | 昆明赛诺制药股份有限公司 | A kind of medicine for treating lung cancer and preparation method thereof |
| CN109010699A (en) * | 2018-10-08 | 2018-12-18 | 陕西中医药大学附属医院 | Anti-lung cancer Chinese medicine composition and preparation method thereof |
| CN114699497A (en) * | 2021-10-27 | 2022-07-05 | 厦门市中医院 | Traditional Chinese medicine composition for improving life quality of patients after lung cancer operation chemoradiotherapy and application thereof |
| CN115212262A (en) * | 2022-09-02 | 2022-10-21 | 北京硒哥硒生物科技有限公司 | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof |
| CN118384252A (en) * | 2024-04-15 | 2024-07-26 | 河南中医药大学第一附属医院 | A Chinese medicine preparation for lung cancer and its preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102805840A (en) * | 2012-08-21 | 2012-12-05 | 亳州康复肿瘤药物研究所 | Complex anti-tumor traditional Chinese medicine preparation |
-
2016
- 2016-05-30 CN CN201610370299.9A patent/CN105878938A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102805840A (en) * | 2012-08-21 | 2012-12-05 | 亳州康复肿瘤药物研究所 | Complex anti-tumor traditional Chinese medicine preparation |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107684566A (en) * | 2017-04-08 | 2018-02-13 | 昆明赛诺制药股份有限公司 | A kind of medicine for treating lung cancer and preparation method thereof |
| CN109010699A (en) * | 2018-10-08 | 2018-12-18 | 陕西中医药大学附属医院 | Anti-lung cancer Chinese medicine composition and preparation method thereof |
| CN114699497A (en) * | 2021-10-27 | 2022-07-05 | 厦门市中医院 | Traditional Chinese medicine composition for improving life quality of patients after lung cancer operation chemoradiotherapy and application thereof |
| CN114699497B (en) * | 2021-10-27 | 2023-08-11 | 厦门市中医院 | Traditional Chinese medicine composition for improving life quality of patient after lung cancer operation chemoradiotherapy and application thereof |
| CN115212262A (en) * | 2022-09-02 | 2022-10-21 | 北京硒哥硒生物科技有限公司 | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof |
| CN118384252A (en) * | 2024-04-15 | 2024-07-26 | 河南中医药大学第一附属医院 | A Chinese medicine preparation for lung cancer and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105878938A (en) | Pharmaceutical preparation for treating lung cancer and application thereof | |
| CN102210820A (en) | Chinese medicinal composition for treating leukemia | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN103316249A (en) | Astragalus taxus chinensis capsule and preparing process thereof | |
| CN102772737A (en) | Traditional Chinese medicine composition for treating liver cirrhosis and fibrosis and preparation method thereof | |
| CN103550506B (en) | A kind of in radiotherapy with the use of Chinese medicine composition | |
| CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
| CN103749818A (en) | Rhizoma polygonati healthcare tea with hypoglycemic and hypolipidemic effects and preparation method thereof | |
| CN105267559B (en) | A kind of drug and preparation method thereof for treating diabete peripheral herve pathology | |
| CN103446445B (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency-type chronic bronchitis and preparation method thereof | |
| CN103989996A (en) | Traditional Chinese medicine composition for treating diabetes and preparation method thereof | |
| CN103263658A (en) | Traditional Chinese medicine preparation for treating peripheral facial paralysis and preparation method thereof | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN107952036B (en) | Traditional Chinese medicine preparation for reducing blood sugar and preparation method thereof | |
| CN101703660B (en) | Anti-aging medicament | |
| CN104587300A (en) | Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition | |
| CN105232677A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method of traditional Chinese medicine composition | |
| CN104524535A (en) | Traditional Chinese medicine composition for treating chronic pulmonary heart disease and preparation method of traditional Chinese medicine composition | |
| CN110694037A (en) | A composition for treating cervical spondylosis, cold and depression | |
| CN102000303B (en) | Compound traditional Chinese medicine preparation for suppressing tumors | |
| CN103110743B (en) | Traditional Chinese medicine composition for treating or preventing neurasthenia and preparation method thereof | |
| CN105920436A (en) | Medicinal preparation for treating lung cancer and preparation method thereof | |
| CN107854539B (en) | A Chinese medicinal composition for treating coronary heart disease, cardiac insufficiency and arrhythmia, and its preparation method | |
| CN104800573A (en) | Chinese medicinal composition for treating liver cancer and preparation method thereof | |
| CN115487264A (en) | Composition for reducing phlegm and removing stasis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160824 |
|
| WW01 | Invention patent application withdrawn after publication |